AXL and melanoma: Apart from the significance of the MITF/AXL ratio in the development of resistance to BRAFi, MITFlow/JARID1Bhigh and MITFhigh/PGC1αhigh (PPARG coactivator 1 alpha) ratios also have been linked to drug resistance in melanoma [245,246].